Home > Healthcare > Pharmaceuticals > Finished Drug Form > Intravenous Iron Drugs Market
Intravenous Iron Drugs Market Size
- Report ID: GMI10898
- Published Date: Aug 2024
- Report Format: PDF
Intravenous Iron Drugs Market Size
Intravenous Iron Drugs Market size was valued at around USD 1.7 billion in 2023 and is estimated to grow at 6.7% CAGR from 2024 to 2032. Intravenous (IV) iron drugs are pharmaceutical formulations of iron administered directly into the bloodstream through intravenous injection or infusion. These drugs are used to treat or prevent iron deficiency anemia, particularly in patients who cannot absorb oral iron supplements effectively or who have conditions that require rapid replenishment of iron stores.
The rising prevalence of chronic diseases such as chronic kidney disease (CKD), cancer, and inflammatory disorders are significant driving factors for the market. For instance, according to the World Health Organization (WHO), in 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths worldwide. This underscores the critical need for effective treatment options, including intravenous iron therapies, to manage anemia associated with these conditions and improve patient outcomes.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Intravenous Iron Drugs Market Size in 2023: | USD 1.7 Billion |
| Forecast Period: | 2024 – 2032 |
| Forecast Period 2024 – 2032 CAGR: | 6.7% |
| 2024 – 2032 Value Projection: | USD 3 Billion |
| Historical Data for: | 2021-2023 |
| No. of Pages: | 132 |
| Tables, Charts & Figures: | 219 |
| Segments covered: | Drug Type, Application, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Furthermore, increasing awareness of the timely diagnosis of iron deficiencies, a growing geriatric population, and advancements in IV iron drug formulations are also contributing to revenue growth in the market.
Frequently Asked Questions (FAQ) :
Intravenous Iron Drugs Market Scope
